Loading live market data…

Sanofi

NASDAQ:SNY

$43.18 USD

-$0.82 (-1.86%)

Volume
2.25M
Average Volume
3.21M
Market Capitalization
$103.82B
P/E Ratio
12.17
Dividend Yield
5.46%
Price Target
$49.50
Year High
$52.68
Year Low
$40.89
Day High
—
Day Low
—
Payout Ratio
$0.63
Current Ratio
$1.01

Industry, Sector & symbol

Stock Exchange NASDAQ
CEO Olivier Charmeil
Industry Drug Manufacturers - General
Sector Healthcare
Current Symbol SNY
CUSIP 80105N105
CIK 0001121404
Web https://www.sanofi.com
Phone 33 1 53 77 40 00
Currency USD
Employees 82878
Country FR

Liquidity

Debt-to-Equity Ratio 0.27
Payout Ratio 0.63
Current Ratio 1.01
Quick Ratio 0.22
Cash Ratio 0.18

Sales & Book Value

Annual Sales $46.72B
Price / Sales 1.91
Cash Flow 12.68
Price / Cash Flow 5.94
Price / Book 1.25

Price Target and Rating

Average Stock Price Forecast $49.50
High Stock Price Forecast $50.00
Low Stock Price Forecast $49.00
Forecast Upside/Downside -12.77%
Consensus Rating Buy
Rating Score(0-5) 4
Research Coverage 27 Analysts

Profitability

EPS (Most Recent Fiscal Year) $3.2
Trailing P/E Ratio 12.17
PEG Ratio -0.80
P/E Growth -0.80
Net Income $7.81B
Net Margin 15.95%
Pretax Margin 12.32%
Return on Equity 10.51%
Return on Assets 5.90%

Financials Score

AltmanZ Score 1.63
Piotroski Score 6.00
Working Capital 156M
Total Assets 128.02B
Ebit 9.28B
Market Cap 92.9B
Total Liabilities 54.88B

Poll Results

About Sanofi (NASDAQ:SNY) Stock

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vac ... cine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Press Release: Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

2026-07-10 08:35:00

Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

US FDA approves Sanofi's wearable injector form of blood cancer drug

2026-07-10 08:22:07

The U.S. Food ​and Drug ‌Administration said on Friday ​it has ​approved Sanofi's blood ⁠cancer drug, ​Sarclisa, which ​can be given under the ​skin through ​a wearable injector, ‌offering ⁠multiple myeloma patients a less burdensome ​alternative ​to ⁠intravenous infusions.

EU seeks feedback on Sanofi's commitments addressing suspected anti-competitive behaviour

2026-07-08 06:00:54

The European Commission said on Wednesday ​it would seek feedback ‌on commitments offered by French pharmaceutical company Sanofi to ​address concerns that ​it may have breached competition ⁠rules in a ​flu vaccine marketing campaign.

SNY's Nexviazyme Meets Goals in Infantile-Onset Pompe Disease Study

2026-07-01 10:26:09

Sanofi's phase III Baby-COMET study meets all goals for Nexviazyme in infantile-onset Pompe disease, paving the way for a planned U.S. filing in H2 2026.

Press Release: Availability of the aide-mémoire for Q2 2026 results

2026-07-01 01:30:00

Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Second quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results.

Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows

2026-06-30 15:04:19

When dividend stocks drop in value, investors have the opportunity to secure some higher-than-typical yields. The stocks listed here haven't been doing well this year, but they offer some attractive dividend income.

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

2026-06-30 07:45:03

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

EU Commission opens antitrust probe into Sanofi's flu vaccine campaign

2026-06-26 05:46:56

The European Commission opened on Friday an ​investigation into whether French ‌drug giant Sanofi breached EU competition rules in a flu ​vaccine marketing campaign.

Frequently Asked Questions

What is the current Sanofi (SNY) stock price?

Sanofi(NASDAQ:SNY) stock price is $43.18 in the last trading session. During the trading session, SNY stock reached the peak price of $52.68 while $40.89 was the lowest point it dropped to. The percentage change in SNY stock occurred in the recent session was --1.86% while the dollar amount for the price change in SNY stock was -$-0.82.

SNY's industry and sector of operation?

The NASDAQ listed SNY is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of SNY?

Thomas Triomphe | Executive Vice President of Vaccines
Olivier Charmeil | Executive Vice President of General Medicines
Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing
Roy Papatheodorou | Executive Vice President & General Counsel
Thomas Kudsk Larsen | Head of Investor Relations & General Medicines

How many employees does SNY have?

Number of SNY employees currently stands at 82878. SNY operates from 54, Rue La BoEtie, Paris, IF 75008, FR.

Link for SNY official website?

Official Website of SNY is: https://www.sanofi.com

How do I contact SNY?

SNY could be contacted at phone #33 1 53 77 40 00 and can also be accessed through its website. SNY operates from 54, Rue La BoEtie, Paris, IF 75008, FR.

How many shares of SNY are traded daily?

The average number of SNY shares traded daily for last 3 months was 3.21M.

What is the market cap of SNY currently?

The market value of SNY currently stands at $103.82B with its latest stock price at $43.18